KYTX logo

Kyverna Therapeutics, Inc.

KYTX
Healthcare|Biotechnology|US
$4.88
+0.27 (+5.86%)
DCF Value
$2.04
Tangible Book / Share
$2.72
Cash / Share
$3.27
Next Earnings Report
Nov 11, 2026
EPS est. -$0.68
Financing Filings (last 12 months)
4
Shelf registrations / offering prospectuses — latest Apr 2, 2026 (424B5). Possible dilution.

Upcoming Data Readouts (6)

Feb 2027
Est. completion
P1Idiopathic Inflammatory Myopathies
CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101
NCT06152172n=24
Apr 2027
Est. completion
P2Multiple Sclerosis, Primary Progressive
KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis
NCT06384976n=120
Jun 2027
Est. completion
P1P2Rheumatoid Arthritis
Comparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Patients With Rheumatoid Arthritis
NCT06475495n=13
Jun 2027
Est. completion
P1Multiple Sclerosis
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
NCT06138132n=12
Sep 2027
Est. completion
P2P3Myasthenia Gravis
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
NCT06193889n=66
Jan 2041
Est. completion
Refractory Lupus Nephritis
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
NCT07403188n=70

Awaiting Results (1)

Trials past primary completion date but still active — data readout may be imminent.

Feb 2026
P1
A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis
NCT06451159

Recent Press Releases

Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference
Nov 5, 2026 · GlobeNewsWire
Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026
Oct 23, 2026 · GlobeNewsWire
Did Kyverna Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Oct 22, 2026 · PRNewsWire
Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS Toronto
Oct 21, 2026 · GlobeNewsWire
Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026
Oct 7, 2026 · GlobeNewsWire
Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis
Sep 24, 2026 · GlobeNewsWire
Kyverna Therapeutics to Present at Upcoming Investor Conferences
Sep 2, 2026 · GlobeNewsWire
Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results
Aug 11, 2026 · GlobeNewsWire

SEC Filings (67)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 19, 2026SC 13GPassive 5%+ stakeDocumentIndex
Sep 24, 20268-KMaterial eventDocumentIndex
Aug 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 11, 202610-QQuarterly reportDocumentIndex
Aug 11, 20268-KMaterial eventDocumentIndex
Jul 29, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jul 27, 20268-KMaterial eventDocumentIndex
Jul 9, 20268-KMaterial eventDocumentIndex
Jun 2, 20268-KMaterial eventDocumentIndex
May 18, 20268-KMaterial eventDocumentIndex
May 12, 202610-QQuarterly reportDocumentIndex
May 12, 20268-KMaterial eventDocumentIndex
May 4, 20268-KMaterial eventDocumentIndex
Apr 22, 20268-KMaterial eventDocumentIndex
Apr 22, 20268-KMaterial eventDocumentIndex
Apr 20, 20268-KMaterial eventDocumentIndex
Apr 13, 2026ARSAnnual report to holdersDocumentIndex
Apr 13, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 13, 2026DEF 14AProxy / shareholder voteDocumentIndex
Apr 2, 2026EFFECTDocumentIndex
Apr 2, 2026424B5Offering prospectusDocumentIndex
Mar 26, 2026S-8Employee stock planDocumentIndex
Mar 26, 2026S-3Shelf registrationDocumentIndex
Mar 26, 202610-KAnnual reportDocumentIndex
Mar 26, 20268-KMaterial eventDocumentIndex
Feb 24, 20268-KMaterial eventDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 6, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 3, 20268-KMaterial eventDocumentIndex
Jan 12, 20268-KMaterial eventDocumentIndex
Dec 18, 20258-KMaterial eventDocumentIndex
Dec 18, 2025424B5Offering prospectusDocumentIndex
Dec 17, 2025FWPDocumentIndex
Dec 15, 2025424B5Offering prospectusDocumentIndex
Dec 15, 20258-KMaterial eventDocumentIndex
Dec 15, 20258-KMaterial eventDocumentIndex
Nov 17, 2025SC 13GPassive 5%+ stakeDocumentIndex
Nov 12, 202510-QQuarterly reportDocumentIndex
Nov 12, 20258-KMaterial eventDocumentIndex